

Table E-6. Study characteristics for trials comparing hormone with hormone

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Polvani 1991	Italy	17	373	RCT Active Compare	2	26		No/NR
Henriksson 1994	Multinational	9	157	RCT Active Compare	2	12		No/NR
Studd 1995	Multinational	19	204	RCT Active Compare	2	12		No/NR
Ayton 1996	Australia	3	194	RCT Active Compare	2	12	Yes	No/NR
Hilditch 1996	Canada	NR	74	RCT Active	2	14	Yes	No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Egarter 1996	Austria	Multi	101	RCT Active Compare	2	26	Yes	No/NR
Hirvonen 1997	Finland	1	120	RCT Active Compare	2	52		No/NR
Hirvonen 1997	Finland	1	173	RCT Active Compare	3	104	Yes	No/NR
Rozenberg 1997	Multinational	35	774	RCT Active Compare	5	52	Yes	No/NR
Al-Azzawi 1997	Netherlands	Multi	394	RCT Active Compare	3	28		No/NR
Lubbert 1997	Germany	469	2459	RCT Active Compare	2	12		No/NR
Barentsen 1997	Netherlands	12	165	RCT Active Compare	2	12		Yes
Bachmann 1997	United States		196	RCT Active Compare	2	15	Yes	No/NR
Good 1999	United States	NR	321	RCT Active Compare	4	12	Yes	No/NR
Mattsson 2000	Multinational	Multi	659	RCT Active Compare	2	24	Yes	No/NR
Saure 2000	Denmark	Multi	376	RCT Active Compare	2	26		No/NR
Graser 2000	Multinational	49	581	RCT Active Compare	3	52	Yes	No/NR
Rioux 2000	Canada	6	159	RCT Active Compare	2	24	Yes	No/NR
Dugal 2000	Norway	Multi	96	RCT Active Compare	2	24		No/NR
Parsey 2000	United	19	193	RCT Active	2	12	Yes	No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
	States			Compare				
Meuwissen 2001	Netherlands	56	634	RCT Active Compare	2	52	Yes	No/NR
Lopes 2001	France	51	361	Crossover	2	12		No/NR
Ozsoy 2002	Turkey	1	201	RCT Active Compare	2	24		No/NR
Loh 2002	Singapore	3	96	RCT Active Compare	2	26		No/NR
Buckler (d) 2003	United Kingdom	21	159	RCT Active Compare	2	24	Yes	No/NR
Lobo 2003	United States		218	RCT Active Compare	2	16	Yes	No/NR
Pornel 2005	Multinational	98	764	RCT Active Compare	2	52		No/NR
Gambacciani 2005	Multinational	4	850	RCT Active Compare	3	104		No/NR
Utian 2005	United States	33	248	RCT Active Compare	3	12	Yes	No/NR
Davis 2005	Multinational	2	120	RCT Active Compare	2	16		No/NR
Raynaud 2005	France	Mult i	405	RCT Active Compare	3	24		No/NR
Braunstein 2005	United States	39	446	RCT Plac Compare	4	24	Yes	No/NR
Simon 2005	Multinational	52	562	RCT Plac Compare	2	24	Yes	Yes
Weisberg 2005	Australia	4	185	RCT Active Compare	2	48	Yes	No/NR
Buster 2005	Multinational	53	532	RCT Plac Compare	2	24	Yes	Yes

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Akhila 2006	India	1	88	RCT Active Compare	3	52		No/NR
Serrano 2006	Italy	4	114	RCT Active Compare	2	52		No/NR
Cieraad 2006	United Kingdom	29	189	RCT Active Compare	2	24		No/NR
Davis 2006	Multinational	15	76	RCT Plac Compare	2	24	Yes	No/NR
Long 2006	Taiwan	1	73	RCT Active Compare	2	12		No/NR
Shifren 2006	Multinational	58	549	RCT Active Compare	2	24	Yes	No/NR
Limpaphayom (m) 2006	Multinational	22	1028	RCT Active Compare	3	24	Yes	No/NR
Odabasi 2007	Turkey	1	61	RCT Active Compare	2	12		No/NR
Pitkin (d) 2007	Multinational	45	459	RCT Active Compare	3	52	Yes	No/NR
Penteado 2008	Brazil	1	56	RCT Plac Compare	2	52	Yes	No/NR
Panay 2010	Multinational	17	272	RCT Plac Compare	2	24	Yes	No/NR

(d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial